SG 418
Alternative Names: HSC fusosome program - Sana Biotechnology; SG-418Latest Information Update: 17 Oct 2023
At a glance
- Originator Sana Biotechnology
- Class Antianaemics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Beta-thalassaemia; Sickle cell anaemia
Most Recent Events
- 12 Oct 2023 Discontinued - Preclinical for Beta-thalassaemia in USA (Parenteral) prior to October 2023 (Sana Biotechnology pipeline, October 2023)
- 12 Oct 2023 Discontinued - Preclinical for Sickle cell anaemia in USA (Parenteral) prior to October 2023 (Sana Biotechnology pipeline, October 2023)
- 15 Jun 2022 Sana Biotechnology plans to file an IND application with the US FDA for Beta-thalassaemia in next several years